|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5596 USD | +0.48% |
|
-1.15% | -3.53% |
| Dec. 18 | RTW Biotech Opportunities announces new investment in Yarrow Bioscience | RE |
| Dec. 17 | VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call |
Company Valuation: VYNE Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 265.2 | 54.59 | 8.705 | 32.52 | 49.42 | 18.63 | 18.63 | - |
| Change | - | -79.42% | -84.05% | 273.57% | 51.96% | -62.31% | 0% | - |
| Enterprise Value (EV) | 265.2 | 54.59 | 8.705 | 32.52 | 49.42 | 18.63 | 18.63 | 18.63 |
| Change | - | -79.42% | -84.05% | 273.57% | 51.96% | -62.31% | 0% | 0% |
| P/E ratio | -0.8x | -0.72x | -0.37x | -0.84x | -3.6x | -0.67x | -0.85x | -0.87x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0.1x | 0.07x | 0x | 0.29x |
| Capitalization / Revenue | 12.6x | 3.7x | 18.3x | 76.7x | 98.6x | 31x | 79.8x | - |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 31x | 79.8x | - |
| EV / EBITDA | - | - | - | -0x | -0x | -0.42x | -0.37x | -0.32x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.49x | -0.42x | -0.28x |
| EV / FCF | -0x | -0x | - | - | - | -0.42x | -0.33x | -0.23x |
| FCF Yield | -51.7% | -103% | - | - | - | -238% | -299% | -434% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -141.8 | -25.56 | -7.28 | -2.78 | -0.93 | -0.84 | -0.66 | -0.64 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 20.99 | 14.76 | 0.477 | 0.424 | 0.501 | 0.6 | 0.2333 | - |
| EBITDA 1 | - | - | - | -29.26 | -43.63 | -44 | -50.7 | -57.7 |
| EBIT 1 | -252.5 | -68.03 | -34.3 | -29.26 | -43.64 | -38.25 | -44.7 | -66.35 |
| Net income 1 | -255.6 | -73.33 | -23.21 | -28.45 | -39.83 | -36.3 | -44.13 | -66.25 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 113.7599 | 18.3600 | 2.7000 | 2.3300 | 3.3500 | 0.5596 | 0.5596 | 0.5596 |
| Nbr of stocks (in thousands) | 2,332 | 2,973 | 3,224 | 13,957 | 14,751 | 33,286 | 33,286 | - |
| Announcement Date | 3/4/21 | 3/17/22 | 3/9/23 | 2/29/24 | 3/6/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.67x | - | - | - | 18.63M | |
| 46.3x | 11.03x | 39.37x | 0.02% | 50.29B | |
| 16.91x | 6.04x | 13.29x | 1.77% | 42.11B | |
| -25.72x | 51.77x | -29.4x | -.--% | 31.96B | |
| -26.38x | 4.43x | -12.22x | -.--% | 26.75B | |
| 30.86x | 6.1x | 16.89x | -.--% | 19.93B | |
| 16.61x | 3.9x | 10.31x | -.--% | 19.08B | |
| -175.88x | 43.39x | -175.79x | -.--% | 12.63B | |
| -306.26x | 24.05x | 1011.94x | -.--% | 11.89B | |
| Average | -47.14x | 18.84x | 109.30x | 0.22% | 23.85B | |
| Weighted average by Cap. | -15.93x | 16.83x | 54.15x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- VYNE Stock
- Valuation VYNE Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
